Advances in chemotherapy for patients with extremity soft tissue sarcoma

被引：9

作者：

Eilber, FC ^{[1
]}

Tap, WD ^{[1
]}

Nelson, SD ^{[1
]}

Eckardt, JJ ^{[1
]}

Eilber, FR ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90095 USA

来源：

ORTHOPEDIC CLINICS OF NORTH AMERICA | 2006年 / 37卷 / 01期

关键词：

D O I：

10.1016/j.ocl.2005.07.001

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does. This benefit is likely histology- and size-specific. Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas.

引用

页码：15 / +

页数：9

共 41 条

[1]

[Anonymous], 2002, PATHOLOGY GENETICS T

[2]

[Anonymous], CANC STAG MAN

[3] AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS [J].

ANTMAN, K ;

CROWLEY, J ;

BALCERZAK, SP ;

RIVKIN, SE ;

WEISS, GR ;

ELIAS, A ;

NATALE, RB ;

COOPER, RM ;

BARLOGIE, B ;

TRUMP, DL ;

DOROSHOW, JH ;

AISNER, J ;

PUGH, RP ;

WEISS, RB ;

COOPER, BA ;

CLAMOND, GH ;

BAKER, LH .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1276-1285

[4]

ANTMAN KH, 1992, SEMIN ONCOL, V19, P13

[5] RESPONSE TO IFOSFAMIDE AND MESNA - 124 PREVIOUSLY TREATED PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA [J].

ANTMAN, KH ;

RYAN, L ;

ELIAS, A ;

SHERMAN, D ;

GRIER, HE .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :126-131

[6]

Borden EC, 2003, CLIN CANCER RES, V9, P1941

[7]

Brennan MF, 2001, CANC PRINCIPLES PRAC, P1841

[8]

Brodowicz T, 2000, Sarcoma, V4, P151, DOI 10.1080/13577140020025869

[9] Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group [J].

Coindre, JM ;

Terrier, P ;

Bui, NB ;

Bonichon, F ;

Collin, F ;

LeDoussal, V ;

Mandard, AM ;

Vilain, MO ;

Jacquemier, J ;

Duplay, H ;

Sastre, X ;

Barlier, C ;

HenryAmar, M ;

Lesech, JM ;

Contesso, G .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :869-877

[10] Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: Chemotherapy-associated outcomes [J].

Cormier, JN ;

Huang, XL ;

Xing, Y ;

Thall, PF ;

Wang, XM ;

Benjamin, RS ;

Pollock, RE ;

Antonescu, CR ;

Maki, RG ;

Brennan, MF ;

Pisters, PWT .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4567-4574

← 1 2 3 4 5 →